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Abstract
Objective: To date, serum free testosterone measurement is considered to be the gold standard for the
diagnosis of hypogonadism in elderly males but it is not available to all subjects suspected of a
decrease in testicular function. Therefore, we evaluated whether the Androgen Deficiency in
Aging Males (ADAM) questionnaire, in its original or in a modified ‘quantitative’ version
(qADAM), could be used as a surrogate to biochemical determinations for the identification of hypo-
gonadism in elderly males.
Methods: 5028 men, aged 50–70 years, spontaneously consulting for the assessment of their gona-
dal function were studied. ADAM and qADAM, allocating a value of 1 point for any positive answer
to each of the 10 questions of the ADAM test, were assessed for their ability to discriminate between
males with free testosterone levels below or above 70 ng/l.
Results: The sensitivity and specificity of the ADAM score were 81% and 21.6% respectively. The use
of ADAM resulted in an appropriate classification of our population in normal or hypogonadal sub-
jects in 44.5% of the cases. The area under the receiver operating characteristics (ROC) curve for
the qADAM (0.529) revealed a highly marginal interest of this quantitative approach compared
with the original scoring system.
Conclusions: The ADAM test has a high sensitivity to identify aging males with low free testosterone
levels. However, due to its lack of specificity, this test cannot be used as a surrogate to serum free
testosterone testing for the identification of androgen deficiency in elderly, community-dwelling males.
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Introduction
During the last century, life expectancy has risen shar-
ply in most developed countries, drawing attention to
physiological or pathological conditions that specifi-
cally affect elderly individuals (1, 2).
In both genders, gonadal function decreases with age
(3). Women at the time of the menopause present a
sudden discontinuation of ovarian activity, resulting
in a drastic decrease of circulating estrogen levels and
a rapid onset of subsequent climacteric symptoms. In
aging men, a more progressive decrease in testosterone
production is observed and has been linked in some
individuals to a complex clinical syndrome, including
physical and psychological alterations, which by ana-
logy with the female menopause has been called andro-
pause (4, 5). Whether andropause is a disorder or a
normal manifestation of aging remains controversial
(5, 6). However, since the development and the com-
mercial availability of chemical entities able to compen-
sate for testosterone deficiency and that have been
shown to improve the quality of life of these aging
males (7–14), much effort has been dedicated to ident-
ify male subjects who should benefit from such hormo-
nal replacement therapy (15 –20). So far, the gold
standard for the diagnosis of primary or secondary
hypogonadism is the serum measurement of free testos-
terone (4). However, as with any laboratory measure-
ment, this requires collection of body fluid and, due
to economic and technical constraints, it is not avail-
able to any single individual suspected of a decrease
in testicular function.
Attempts were made to develop simple, user-friendly,
non-invasive tools that would identify andropausal men
on the basis of their clinical presentation (21 –25).
While preliminary results obtained with some of these
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tools are promising, their surrogacy to the biochemical
measurement of circulating androgen levels has not
been unequivocally demonstrated.
The objective of our study was to evaluate whether a
simple, self-administered questionnaire, the Androgen
Deficiency in Aging Males (ADAM) score (23) could
be used as a surrogate to serum free testosterone testing
for the identification of androgen deficiency in elderly
community-dwelling males. We also designed a modi-
fied ‘quantitative’ version of the score and compared
its diagnostic value with the results obtained with the
original tool.
Material and methods
As part of the European Health Education program of
the World Health Organisation, all men aged 50–70
years and living in the Lie`ge area (n ¼ 12 796) were
invited by the Health Authority of the Province of
Lie`ge to attend a free screening campaign aimed at
the detection of prostatic cancer and andropause.
A venous fasting blood sample was drawn between
0900 and 1130 h for the assessment of total testoster-
one, sex hormone binding globulin (SHBG), follicle-sti-
mulating hormone (FSH) and luteinizing hormone
(LH). The samples were immediately centrifuged and
frozen at 270 8C. All determinations were performed
using commercially available electrochemilumines-
cence immunoassays (ECLIA). Total testosterone,
SHBG, LH and FSH were measured using the Elecsys
Systems 2010 (Roche, Basel, Switzerland). For total tes-
tosterone, the intra- and interassay coefficients of vari-
ation (CV) varied from 0.9 to 4.6% and from 1.6 to
7.4% respectively. For SHBG, the intra- and interassay
CV varied from 2.1 to 2.7% and from 2.6 to 5.6%
respectively. For LH, the intra- and interassay CV
varied from 0.8 to 1.8% and from 1.9 to 5.2% respect-
ively. For FSH, the intra- and interassay CV varied from
1.4 to 2.0% and from 2.9 to 5.3% respectively.
Free testosterone (FT) was indirectly obtained by the
calculation of the formula developed and validated by
Vermeulen et al. 1999 (26):
½FT ¼ ½T2 N* ½FT
KSHBG* {½SHBG2 ½T þ N* ½FT}
where N ¼ 1 þ KA* [A], [T] ¼ total serum testosterone
concentration in mol/l, [SHBG] ¼ sex hormone binding
globulin serum concentration in mol/l, [A] ¼ serum
albumin concentration in mol/l, KSHBG ¼ affinity
constant of testosterone for SHBG ¼ 1 £ 109 mol/l,
KA ¼ affinity constant of testosterone for
albumin ¼ 3.6 £ 104 mol/l.
Based on the previous study (27), andropause was
considered to be present when free testosterone was
,70 ng/l. This free testosterone threshold is similar
to the mean value 22 standard deviations (S.D.)
(74 ng/l) obtained in healthy young males 20–40
years of age (28). There is no generally accepted cut
off value of free testosterone for defining androgen
deficiency, but it is commonly accepted that 2 S.D.
below normal values for healthy young men is abnor-
mal (5, 28).
Participants were then asked to answer the pre-
viously described (27) French version of the Androgen
Deficiency in Aging Males (ADAM) questionnaire (23).
The ADAM questionaire consists of ten items describing
the most common symptoms observed in androgen
deficiency and is divided into three dimensions i.e.
energy, mood and sexual disorders. The original devel-
oper of ADAM considered the test to be positive (A þ ) if
the subject gives a positive answer to any of the ques-
tions pertaining to sexual disorders or to at least
three of the other questions. The test is considered to
be negative (A 2 ) in all other cases (Table 1) (23).
We assessed the sensitivity (i.e. the probability that a
patient with free testosterone ,70 ng/l has a positive
ADAM test), the specificity (i.e. the probability that a
patient with free testosterone $70 ng/l has a negative
ADAM test), the positive predictive value (PPV) (i.e.
the probability that a patient with a positive ADAM
test has a free testosterone ,70 ng/l) and the negative
predictive value (NPV) (i.e. the probability that a
patient with a negative ADAM test has a free testoster-
one $70 ng/l) of ADAM in the perspective of the identi-
fication of men with andropause. The global efficiency
of ADAM was defined by the percentage of subjects
who are correctly classified as either hypogonadic or
normal.
We also designed a modified ‘quantitative’ assess-
ment of the ADAM questionaire (qADAM) in which
we allocated the value of 1 to a positive answer to
any of the questions, allowing the calculation of a
global qADAM score, summing all values, and ranging
from 0 to 10. We assessed the interest of the qADAM
score for separating individuals with free testosterone
,70 ng/l from those with free testosterone $70 ng/l,
by means of Chi-square and unpaired Student’s t-test
(STATISTICA 5.0, Statsoft, Maisons-Alfort, France).
The receiver operator characteristics (ROC) curve of
the qADAM for free testosterone ,70 ng/l was calcu-
lated. The area under the ROC curve provides a
measure of the ADAM’s discriminating power. An
area of 1 suggests perfect separation between normal
and hypogonadal men, while an area of 0.5 indicates
a nondiscriminating test. A two-tailed level of 5% was
considered statistically significant.
Results
From September 2000 to January 2003, 127 796
elderly men were invited to perform the screening
tests for prostatic cancer and andropause; 18.7% of
them spontaneously attended the screening for pros-
tatic cancer, whereas for andropause, the response
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rate was 3.9% (n ¼ 5028). The mean age (S.D.) of our
sample was 60.0 (5.8) years. The prevalence of hypo-
gonadism (free testosterone ,70 ng/l) was 38.6%
(n ¼ 1939). A positive ADAM score (A þ ) was
reported in 3993 men (79.4%). The A þ patients
were significantly older (60.4 (5.3) years) than the
A 2 patients (58.4 (5.6) years) (P , 0.001). Table 2
shows the serum hormones levels in the two groups
(A þ /A 2 ). FSH was the only parameter which sig-
nificantly differed between the two groups (P , 0.04).
Table 3 summarizes the percentage of positive
answers for all questions of the ADAM score, in the
whole sample and in men with free testosterone
below or above 70 ng/l. A higher proportion of A þ
(following the definition of the developer) was observed
in the group of men with free testosterone ,70 ng/l
(81.0% vs 78.4%, P ¼ 0.03). A statistically significant
difference between men with free testosterone , or
$70 ng/l was observed for items 1 (libido), 4 (loss of
height), 7 (erectile function) and 10 (work perform-
ance). When assessing the determinants of the statisti-
cal difference in ADAM between men with low and
normal free testosterone, we noticed that these results
are driven by the rates of positive answers to the
questions pertaining to sexual disorders. No significant
difference was observed in the percentage of subjects
with low or normal free testosterone who had answered
positively to ‘any other three questions’ of the ADAM
questionaire (Table 3).
When calculating the qADAM score, there was a sig-
nificant difference between hypogonadal men and
normal subjects (4.3^2.6 vs 4.1^2.6; P ¼ 0.03).
However, when excluding items 1 and 7 which are
related to sexual disorders (modified qADAM score ran-
ging between 0 and 8), a statistical difference was no
longer observed between the two groups (3.07^2.2
vs 3.12^2.2; P ¼ 0.34).
The ROC curve of the qADAM for the free testoster-
one cutoff of 70 ng/l is shown in Fig. 1. The area
under the curve was 0.519 (P ¼ 0.025), indicating
Table 2 Hormonal values in individuals with positive (A þ ) or







(n ¼ 3993) P-value
TT (mg/l) 4.77 (1.79) 4.86 (1.60) 4.75 (1.84) 0.09
FT (ng/l) 81.81 (32.07) 83.20 (30.75) 81.45 (32.40) 0.11
LH (mUI/ml) 5.00 (3.52) 4.93 (3.61) 5.02 (3.50) 0.46
FSH (mUI/ml) 7.01 (6.62) 6.56 (5.54) 7.13 (6.87) 0.04
TT, total testosterone; FT, free testosterone.
Table 1 The Androgen Deficiency in Aging Males (ADAM) questionnaire.
Original version* French translation**
1. Do you have a decrease
in libido (sex drive)?
1. Avez-vous constate´ une diminution de votre libido (de´sir d’avoir des rapports sexuels)?
2. Do you have a lack
of energy?
2. Sentez-vous un manque d’e´nergie?
3. Do you have a decrease
in strength and/or endurance?
3. Sentez-vous une diminution de force musculaire et d’endurance a` l’effort?
4. Have you lost height? 4. Avez-vous remarque´ que vous avez rapetisse´?
5. Have you noticed a decreased
‘enjoyment of life’?
5. Avez-vous remarque´ une diminution de votre joie de vivre?
6. Are you sad and/or grumpy? 6. Vous sentez vous triste et/ou grincheux?
7. Are your erections less strong? 7. Vos e´rections sont-elles moins fortes?
8. Have you noted a recent
deterioration in your ability to
play sport?
8. Avez-vous remarque´ une diminution de votre capacite´ a` ‘faire du sport’?
9. Are you falling asleep after
dinner?
9. Tombez-vous endormi apre`s les repas?
10. Has there been a recent
deterioration in your work performance?
10. Avez-vous remarque´ une diminution re´cente de votre capacite´ de travail?
Affirmative answers to questions 1 or 7, or to any three other questions provide a positive result on the ADAM questionnaire.
* Morley et al. (23); **Legros & Delhez (27).
Figure 1 Receiver operating characteristics (ROC) curve of
qADAM for free testosterone ,70 ng/l. Diagonal segments are
produced by ties. The area under the diagonal represents 50% of
the total area under the maximal ROC curve.
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that the quantitative score (qADAM) provides statisti-
cally better information than random (0.5), even if
this improvement remains highly marginal.
Table 4 summarizes sensitivity, specificity, positive
predictive value, negative predictive value and the
global efficiency of ADAM for the detection of subjects
with low free testosterone levels, based on various cut-
offs of serum free testosterone levels.
The global efficiency of the ADAM test, i.e. the per-
centage of subjects who were appropriately classified
as either hypogonadic or normal, based on the results
of ADAM, varies between 28.7% and 59.3% for free
testosterone cutoffs of 50 ng/l and 90 ng/l respectively.
For the cutoff of 70 ng/l, the global efficiency of ADAM
as a screening test for andropause is 44.5%.
Discussion
The noninvasive ADAM screening test was initially
developed in a cohort of Canadian physicians aged 40
years and over (23). The French translation, used in
the present study, was tested for the first time in a
cohort of Western European (Belgian) males, aged
between 50 and 70 years, spontaneously participating
in a program assessing their hormonal status (27). We
performed the present trial in a larger sample (5028
elderly men) recruited on the same basis. Our
population differs from the sample used in the initial
validation of the ADAM test by their degree of edu-
cation (lay people versus physicians) and by the process
of recruitment (volunteers spontaneously testing their
gonadal function versus randomly chosen physicians).
The mode of selection of our population may explain
the relatively high prevalence of hypogonadism (free
testosterone ,70 ng/l; 38.6%) compared with the
figure of 25% (bioavailable – free and weakly bound
to albumin – testosterone ,70 ng/ml) reported in
the original population (23). The difference in the defi-
nition of hypogonadism between the two studies (‘free’
versus ‘bioavailable’ testosterone ,70 ng/l) may also
be a factor in explaining the discrepancies observed in
the prevalence of hypogonadism. The objective of the
present trial was not to report the exact prevalence of
hypogonadism in community-dwelling, elderly men
living in our area but to evaluate whether a simple,
self-administered questionnaire, the Androgen
Deficiency in Aging Males (ADAM) score, could be
used as a surrogate to serum free testosterone testing
for the identification of androgen deficiency. We also
aimed at the assessment of a modified ‘quantitative’
version of the score (qADAM) and compared its diag-
nostic value with the results obtained with the original
tool (23).
At the cutoff value of 70 ng/l for free testosterone,
the sensitivity and specificity of the ADAM test, in our
population, were 81.0% and 21.6% respectively.
These values are in agreement with the values pre-
viously reported in a similar population (sensitivity
from 80.14% (27) to 82.2% (29, 30) and specificity
from 32.23% (27) to 34.8% (30)). That the free testos-
terone threshold is associated with optimum sensitivity
was previously demonstrated by Legros & Delhez (27).
While the sensitivity is in the same range as reported
in the population of Canadian physicians (23) used
for the initial validation of the ADAM score (88%),
the specificity obtained in our study is significantly
lower than described in that paper (60%). This may
also reflect the difference in the two populations. In
our study, elderly men with symptoms suggestive, but
Table 3 Prevalence (%) of positive answers for the 10 items of the ADAM questionnaire in the total sample and in men with free
testosterone level below or above 70 ng/l.
Item Question’s topic Total (n ¼ 5028) < 70ng/l (n ¼ 1939) $ 70ng/l (n ¼ 3088) P-value (,70 vs $ 70)
1 Libido 50.5 54.7 47.9 ,0.001
2 Energy 53.3 53.9 52.9 0.49
3 Strength endurance 57.7 58.6 57.1 0.30
4 Height 15.1 17.2 13.8 0.001
5 Enjoyment of life 22.9 21.9 23.6 0.15
6 Sad/grumpy 24.4 24.5 24.4 0.98
7 Erections 59.4 61.6 58.0 0.01
8 Playing sport 49.5 49.5 49.5 0.96
9 Sleeping after dinner 50.7 49.7 51.2 0.30
10 Work performance 35.2 37.2 34.0 0.02
Q1 or Q7 67.6 70.9 65.5 ,0.001
Any other 3 questions 57.6 58.3 57.2 0.43
Table 4 Performance of the ADAM questionnaire for various
cutoffs of free testosterone.
Validity criteria
of ADAM test
Free testosterone cutoff point (ng/l)
50 60 70 80 90
Sensitivity (%) 81.4 81.3 81.0 80.4 79.8
Specificity (%) 20.9 21.2 21.6 21.6 21.4
PPV (%) 13.2 26.0 39.3 52.7 65.3
NPV (%) 88.4 76.9 64.4 50.3 36.4
Efficiency (%) 28.7 36.5 44.5 52.2 59.3
PPV, positive predictive value; NPV, negative predictive value.
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not pathognomonic, of hypogonadism may be more
prone than healthy people to attend the screening
spontaneously. This may lead to the recruitment of a
large population for whom symptoms resulting in a
positive answer to one or more questions from the
ADAM score may be linked to co-morbidities mimicking
the clinical expression of hypogonadism. In a previous
study (30), performed in a similar population as the
one used in the present trial, and also reporting low
values for ADAM score specificity, a high prevalence
of depressed mood was reported in males with a positive
ADAM test and normal free testosterone levels. In this
particular trial, the Caroll Rating Scale (CRS) (31), a
widely accepted depression scale, was significantly cor-
related to the ADAM test results (r ¼ 0.66, P , 0.05).
Patients with a positive ADAM test and normal free tes-
tosterone levels had a poorer general well-being based
on the CRS, the social dysfunction of the General
Health (GH-28) instrument and the World Health
Organisation Quality of Life questionnaire (WHOQOL),
compared with patients with a negative ADAM test
and normal free testosterone levels. While we have
not specifically assessed the psychological status of
our patients, this may be an explanation for the poor
specificity of the ADAM test observed in our trial. The
absence of significant differences in free or total testos-
terone levels between A þ and A 2 subjects is another
expression of the poor specificity of this test in our
population.
In our study, the items most frequently associated
with low levels of free testosterone were those pertain-
ing to the sexual dimension (libido and strength of erec-
tions) and those associated with muscular strength and
energy. These items were also associated with the high-
est prevalence of positive answers in males with low tes-
tosterone levels in the initial Canadian publication (23).
In both studies, a deficit in the strength of erections is
the item most frequently reported by males with low
testosterone.
Globally, the overall efficiency of the ADAM score in
our population of male volunteers is disappointing,
mainly due to its poor specificity. When considering
the diagnosis of hypogonadism in males with free tes-
tosterone levels below 70 ng/l, the ADAM score has
an overall efficiency of 44.5%, reflecting an appropriate
classification of males in hypogonadism or not in less
than 50% of the cases. These disappointing results,
denying the use of a simple questionnaire as a surro-
gate to serum free testosterone testing, were also
reported with other questionnaires. T’sjoen et al. inves-
tigated the relationships between male climacteric
symptoms assessed by the Aging Male Symptoms
(AMS) questionnaire with circulating androgen levels
(32). In a population of 161 healthy, elderly, commu-
nity-dwelling ambulatory men aged 74–89 years,
this 17-item scale, consisting of three dimensions
(psychological, somatovegetative and sexual) was
not correlated with free testosterone serum levels.
The authors concluded that climacteric symptoms in
males assessed with the AMS scale failed to predict
androgen levels. This conclusion supports our own
results. These consistent results confirm the extreme
difficulty of developing a questionnaire based on signs
and symptoms as a potential surrogate to biochemical
determinations. In a complex syndrome, as andropause
is in aging males, hormonal levels and physical or
psychological complaints may reflect different but
complementary aspects of the problem. This perception
raises the issue of the validity of a single measurement
of testosterone (absence of information about the indiv-
idual lifetime hormone profile of a subject) to character-
ize an individual as andropausal. Due to the complexity
of the clinical presentation of the andropausal state,
it may be that measurement of clinical symptoms or
quality of life is a better way of assessing patients in
this particular category. At any rate, screening tests
are frequently characterized by high sensitivity and
a relatively low specificity, and may be considered
as particularly useful in identifying patients who
should not be submitted to further investigations.
In several disorders, their ability to select patients
with a high risk of presenting the disease has been
questioned. We and others have previously reported
similar findings for a clinical questionnaire as a surro-
gate to bone densitometry testing in postmenopausal
osteoporosis (33).
We also investigated whether a modified quantitative
version of the ADAM score (qADAM) would be more
effective for the identification of hypogonadal males.
Our results do not support this hypothesis. The area
under the curve calculated for the qADAM score
used for the identification of patients with free
testosterone levels below 70 ng/l, while reaching the
level of statistical significance, is of extremely poor
clinical relevance. The qADAM score does not provide
any significant benefit compared with the original
tool (23).
In conclusion, our results suggest that the ADAM
test has a high sensitivity to identify aging males with
low free testosterone levels. However, due to its lack of
specificity, mainly observed in the population of males
spontaneously consulting for assessment of their gona-
dal function, this test, in its original version or in a
modified quantitative version, cannot be used as a sur-
rogate to serum free testosterone testing for the identi-
fication of androgen deficiency in elderly, community-
dwelling males.
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